Quarterly ResultMay 11, 2026, 04:23 PM
AbCellera Q1 Revenue $8.32M, Net Loss $(43.17)M
AI Summary
AbCellera Biologics Inc. reported its first-quarter 2026 financial results, showing an increase in total revenue to $8.32 million, up from $4.24 million in the prior year's quarter. The company also saw an improvement in its net loss, which narrowed to $(43.17) million from $(45.62) million year-over-year. Despite the revenue growth and reduced net loss, cash and cash equivalents decreased, and net cash used in operating activities significantly increased, reflecting ongoing investment in research and development as a clinical-stage biotechnology company.
Key Highlights
- AbCellera's total revenue increased to $8.32 million in Q1 2026, up from $4.24 million in Q1 2025.
- Net loss improved to $(43.17) million in Q1 2026, compared to $(45.62) million in Q1 2025.
- Basic and diluted net loss per share was $(0.14) in Q1 2026, an improvement from $(0.15) in Q1 2025.
- Cash and cash equivalents decreased to $77.06 million as of March 31, 2026, from $128.51 million at December 31, 2025.
- Research and development expenses rose to $46.66 million in Q1 2026 from $42.50 million in Q1 2025.
- Net cash used in operating activities increased to $(33.52) million in Q1 2026 from $(11.55) million in Q1 2025.
- Marketable securities increased to $427.67 million as of March 31, 2026, from $405.31 million at December 31, 2025.
Price Impact
More from ABCL